PHOENIX was a Phase 2, open-label, multi-center, US-only trial with four separate cohorts of patients with ADPKD, IgAN, T1D CKD, or FSGS. Bardoxolone methyl treatment in patients with T1D CKD resulted in significant increase in kidney function as measured by eGFR at Week 12 from baseline.
- Type 1 diabetes (T1D) affects an estimated 1.25 million people in the US and CKD affects approximately 10-20% of patients with T1D or roughly 150,000 people in the US.
- Bardoxolone methyl significantly improved eGFR (+5.5 mL/min/1.73 m²) from baseline in patients with T1D CKD.
- Bardoxolone methyl was well-tolerated without any drug-related SAEs, changes in blood pressure, or evidence of fluid overload.